Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT00070941) enrolled 29 people across three groups: 12 received a supplement called SAM-e, 11 received a medication called escitalopram, and 6 received a placebo (an inactive treatment). The trial was measuring changes in depression symptoms using a standard questionnaire called the Hamilton Depression Scale, where higher scores indicate more severe depression symptoms and lower scores indicate fewer symptoms. Notably, the number of participants who completed the trial was very small — only 2, 3, and 2 people finished in each group respectively, meaning the large majority did not complete the study. The reported data shows that at the start of the trial, the average Hamilton Depression Scale scores were 17 for the SAM-e group, 17.5 for the escitalopram group, and 20.7 for the placebo group — all falling roughly in the moderate-to-severe range on the scale. By the end of the trial, the reported average scores had shifted to 11.4 for the SAM-e group, 5.3 for the escitalopram group, and 16.2 for the placebo group. The scale used in this trial runs from 0 to 29, with scores of 8–13 considered mild and 0–7 considered no depression. No additional outcome measures or statistical comparison data were reported in the submitted results. It is important to note that because so few participants completed this trial, the numbers above are based on very small groups and should be interpreted with considerable caution. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Parkinson's Disease Trial, Completed
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- You have been diagnosed with Parkinson's disease and show at least two of these signs: shaking at rest, muscle stiffness, slowness of movement, or balance problems
- Your Parkinson's medications have stayed the same for at least 4 weeks before joining the study
- You have not taken any antidepressant or antipsychotic medications in the 30 days before joining
- You agree not to start any new medications, talk therapy, or behavioral therapy while in the trial
- You are using an acceptable form of birth control
- You are able to read and/or follow instructions given in written or spoken English
- You have enough mental clarity to understand and agree to take part (confirmed by a short memory and thinking test)
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- You have significant heart, liver, kidney, blood, breathing, hormone, blood vessel, or other serious health conditions that study doctors consider medically relevant
- You have certain abnormal results on blood or lab tests
- You are currently pregnant or breastfeeding
- You have taken an experimental drug within the 3 months before joining
- You have used St. John's Wort or any other natural supplement known to affect mood in the 30 days before joining
- You have taken selegiline or a similar type of medication (called MAO inhibitors) within 6 weeks before joining
- You regularly take anti-anxiety medications or routinely use sleep aids (occasional use of temazepam, melatonin, or zolpidem may be allowed — confirm with trial site)
- You started any form of talk therapy or psychotherapy within the 6 months before joining
- You have a history of bipolar disorder, mania, schizophrenia, or another psychotic condition
- You have made a serious suicide attempt in the past 12 months, or are currently considered at serious risk of suicide
- You are currently using certain medications that block dopamine (such as metoclopramide or haloperidol)
- Your Parkinson's-like symptoms are caused by medications, a metabolic condition, stroke-related disease, brain infection, or another degenerative disease (rather than true Parkinson's disease)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
If you need support right now
This page includes language about suicide and self-harm, because that is how the trial's eligibility criteria are written. If reading it has been hard, you do not have to keep going. The services below are free, confidential, and answered by people trained for exactly this.
If you or someone else is in immediate danger, call 000.
- Lifeline — 24/7 crisis support: 13 11 14
- Suicide Call Back Service — 24/7 counselling: 1300 659 467
- 13YARN — 24/7, for Aboriginal and Torres Strait Islander people: 13 92 76
- Beyond Blue — 24/7 mental health support: 1300 22 4636
- Emergency: 000
Outside Australia? The numbers above are Australian and will not work from overseas. Find a Helpline is a free directory of crisis lines in over 130 countries, run by ThroughLine with the International Association for Suicide Prevention. If you are in immediate danger, call your local emergency number.
Voxsanity is not a crisis service, and nothing on this page is medical advice. More Australian services are listed on our support lines page.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial was run
These are the locations recorded on the registry, and they are a historical record: this trial is not enrolling, so they are not places you can join it.
Primary endpoints
Change in Hamilton Depression Scale
Other options
Data last synced from ClinicalTrials.gov: 30 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.